Scientific Poster Presentations, II

Tuesday, October 18
Convention Center: Exhibit Hall A
8:00 a.m.–10:00 a.m.

ENCORE PRESENTATIONS
Abstracts marked with an “E” are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2011 Annual Meeting. For presentations, the abstract title, authors, and original citation (if provided) are published.

FINALISTS IN ABSTRACT AWARDS COMPETITION
Abstracts marked with an “F” are finalists for the Best Resident and Fellow Poster, and Best Paper Awards. These papers were selected by a special panel of reviewers. Award winners for the Best Resident and Fellow Poster and Best Paper will be announced at 9:45 a.m. Tuesday, October 18, in Exhibit Hall A of the David L. Lawrence Convention Center.

ORIGINAL RESEARCH
These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

ADR/Drug Interactions

3F. Incidence, Characteristics, and Outcomes of Adverse Drug Events Resulting in Intensive Care Admission in Oncology Patients.

Lama H. Nazer, Pharm.D., BCPS, Feras I. Hawari, M.D., Rana A. Eljaber, Pharm.D.; King Hussein Cancer Center, Amman, Jordan

Cardiovascular

21E. Lipid Target Attainment by Switching Statin Monotherapy to Fenofibric Acid + Statin in Patients with Mixed Dyslipidemia and at High/Highest Risk for Coronary Heart Disease.

Peter H. Jones, M.D.,¹ Syed M. Mohiuddin, M.D.,² Christie M. Ballantyne, M.D.,¹ Michael H. Davidson, M.D., FACC, FACP,³ Kamlesh Thakker, BSPharm, Ph.D.,¹ Carolyn M. Setze, M.S.,³ Aditya Lele, M.S.,³ Maureen T. Kelly, M.D.¹; (1)Baylor College of Medicine, Houston, TX; (2)Creighton Cardiac Center, Omaha, NE; (3)University of Chicago, Pritzker School of Medicine, Chicago, IL; (4)Abbott, Abbott Park, IL

22E. Long-term Efficacy and Safety of Fenofibric Acid in Combination with Statins in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus.

Maureen T. Kelly, M.D.,¹ Kamlesh M. Thakker, BSPharm, Ph.D.,¹ Carolyn M. Setze, M.S.,¹ Inderjit S. Mandair, M.D.,² Patrick Aubonnet, M.D.²; (1)Abbott, Abbott Park, IL; (2)Abbott, Allschwil, Switzerland
23. Dose Escalation of Beta Blocker Therapy Following Initiation of Cardiac Resynchronization Therapy.
Frank A. McGrew, M.D.,1 Eric E. Johnson, M.D.,1 Mark A. Coppess, M.D.,1 Jessica Foon, B.S.,1 Thomas A. Charlton, B.S.,2 Sandy Charlton, BSN,2 J. Jason Sims, Pharm.D.2; (1) Stern Cardiovascular Foundation, Germantown, TN; (2) Medtronic, Mounds View, MN

Matthew Agosti, Pharm.D., Nicholas Bacon, Pharm.D. Candidate, Nicholas B. Norgard, Pharm.D.; University at Buffalo–School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY

25E. Aspirin Reduces Transient Flushing and Glucose Increases During Therapy with Niacin Extended Release.
Robert J. Padley, M.D.,1 Roopal B. Thakkar, M.D.,1 Ping Jiang, M.S.,1 Scott L. Krause, BSN, BS(L&S),1 Michael H. Davidson, M.D., FACC, FACP,2 Henry A. Punzi, M.D.; (1) Abbott, Abbott Park, IL; (2) The University of Chicago Pritzker School of Medicine, Chicago, IL; (3) Texas Women’s University, Dallas, TX

26E. Aliskiren/Valsartan Combination Is More Effective than Valsartan Monotherapy in Dipper and Non-dipper Hypertensive Patients.
Thomas D. Giles, M.D.,1 Thomas Alessi, M.D.,2 Das Purkayastha, Ph.D.,2 Dion H. Zappe, Ph.D.; (1) Tulane University School of Medicine, New Orleans, LA; (2) Novartis Pharmaceuticals Corp, East Hanover, NJ

27. Left-Ventricular Assist Device Implantation Does Not Alter the Pharmacodynamic Response to Warfarin.
Douglas L. Jennings, Pharm.D., BCPS (AQ-CV), Celeste Williams, M.D., Robert Brewer, M.D.; Henry Ford Hospital, Detroit, MI

28. Lack of Significance Between Use of Statins and Cardiovascular Events in Carriers of the Kinesin Family Member 6 Gene 719 Arginine Allele.
Randall P. Sharp, Pharm.D., BCPS,1 Lisa A. Appeddu, Ph.D.,2 Akm Islam, MBBS,3 Riaz Sirajuddin, M.D.; (1) Southwestern Oklahoma State University College of Pharmacy, Weatherford, OK; (2) Southwestern Oklahoma State University School of Health Sciences, Weatherford, OK; (3) Heart Solutions of Oklahoma, Oklahoma City, OK

29. The Impact of a Clinical Pharmacist on a Cardiovascular Surrogate Endpoint: A Pilot Study.
Toni L. Ripley, Pharm.D.,1 Donald L. Harrison, Ph.D.,1 Tiffany Sanders, Pharm.D., Student,1 Thomas A. Hennebry, M.D.,2 R. Chris Rathbun, Pharm.D.; (1) University of Oklahoma College of Pharmacy, Oklahoma City, OK; (2) University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, OK

30. Description of Antihypertensive Use in Patients with Resistant Hypertension Prescribed Four or More Agents.
Michele R. Hanselin, Pharm.D., Joseph J. Saseen, Pharm.D., Richard R. Allen, M.S., Joel C. Marrs, Pharm.D., BCPS, Kavita V. Nair, Ph.D.; University of Colorado School of Pharmacy, Aurora, CO
31. Does Magnesium l-Lactate Improve Quality of Life in Patients with an Implantable Cardioverter Defibrillator?

William L. Baker Jr, Pharm.D., Jeffrey Kluger, M.D., C. Michael White, Pharm.D., FCCP, FCP; Krista D. Riche, Pharm.D., BCPS, Craig I. Coleman, Pharm.D.; (1)University of Connecticut School of Pharmacy, Farmington, CT; (2)Hartford Hospital, Hartford, CT; (3) University of Connecticut, Hartford, CT; (4)Mississippi Baptist Medical Center, Jackson, MS

32E. Cardiac Events, Infections, and Bleeds Contribute to Higher Vascular and Non-vascular Mortality with Clopidogrel Compared to Ticagrelor Treatment in Patients Undergoing Coronary Artery Bypass Grafting.

Christoph M.H. Varenhorst, M.D., Ph.D., Ulrica Alström, M.D., Benjamin M. Scirica, M.D., MPH; Charles W. Hogue, M.D., Nils Åsenblad, PhLic, M.S., Jay Horrow, M.D., M.S., Gunnar Brandrup-Wognsen, M.D., Ph.D., Lars Wallentin, M.D., Ph.D.; Claes Held, M.D., Ph.D.; (1)Uppsala Clinical Research Center, Uppsala, Sweden; (2)Uppsala University, Uppsala, Sweden; (3)TIMI Study Group/Brigham and Women’s Hospital, Boston, MA; (4)The Johns Hopkins University School of Medicine, Baltimore, MD; (5) AstraZeneca, Wilmington, DE; (6)AstraZeneca, Mölndal, Sweden

33. Meta-analysis of the Relationship Between Aspirin Dosing and Efficacy and Bleeding Outcomes in Medically Managed Patients with Acute Coronary Syndromes (ACS).

Jeffery S. Berger, M.D., M.S., FACC, FAHA, Rachel H. Sallum, B.S., B.A., Brian G. Katona, Pharm.D., Juan Maya, M.D., M.S., Gayatri Ranganathan, M.S., Mkaya Mwamburi, M.D., Ph.D.; (1)New York University Medical Center, New York, NY; (2) United BioSource Corp, Lexington, MA; (3)AstraZeneca LP, Wilmington, DE; (4)Tufts University School of Medicine, Boston, MA

34. Comparative Effectiveness of Endothelin Receptor Antagonists for the Treatment of Pulmonary Arterial Hypertension (A Pilot Study).

Heather A. Wong, Pharm.D., Shirley Yan, B.S., Dana P. McGlothlin, M.D., Jaekyu Shin, Pharm.D.; University of California, San Francisco, San Francisco, CA

35. Changes in RIFLE Criteria After Coronary Artery Bypass Graft Surgery in Patients with Recent Exposure to Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.

Jennifer L. Neill, Pharm.D., Shannon W. Finks, Pharm.D., Ronald L. Braden, Pharm.D., Kelly C. Rogers, Pharm.D.; (1)Veterans Affairs Medical Center, Memphis, TN; (2) University of Tennessee College of Pharmacy, Memphis, TN

36. National Cholesterol Education Program (NCEP) Lipid Goal Achievement Beyond Low-Density Lipoprotein Cholesterol (LDL-C) in Patients with Diabetes Mellitus (DM): Focus on Non–High-Density Lipoprotein Cholesterol (nonHDL-C) in the Practice Innovation and Cl.

Sarah Spinler, Pharm.D., Mark J. Cziraky, Pharm.D., Paul F. Chan, M.D., M.S., Fengming Tang, M.S., Thomas M. Maddox, M.D., M.S., Tyan Thomas, Pharm.D., Gladys G. Duenas, Pharm.D., Jennifer A. Reinhold, Pharm.D., Vincent J. Willey, Pharm.D.; (1)Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA; (2) HealthCore, Inc, Wilmington, DE; (3)St. Luke’s Mid-America Heart Institute, Kansas City, MO; (4)Denver VA Medical Center, Cardiology Section, Denver, CO
Scientific Poster Presentations, II

37. A Comparison of Management Strategies in Patients with Acute Coronary Syndrome Based on Clopidogrel Use.
Paul P. Dobesh, Pharm.D., 1 Julie H. Oestreich, Pharm.D., Ph.D., 1 Sarah M. Hanigan, Pharm.D., 2 Hiedi L. Brink, Pharm.D., 1 Sloane M. Schneider, Pharm.D., 1 Janelle M. Weber, Pharm.D., 1; (1) University of Nebraska Medical Center, Omaha, NE; (2) The Nebraska Medical Center, Omaha, NE

38. Increasing the Efficacy of Heparin Infusions Through Computer-Calculated Weight-Based Infusions with Auto-populated Infusion Doses and Partial Thromboplastin Time Orders.
Lindsay M. Arnold, Pharm.D., Paul Huiras, Pharm.D., BCPS; Boston Medical Center, Boston, MA

39. Determinants of Worsening Renal Function with Diuretic Dose Escalation in a Chronic Heart Failure Ambulatory Population.
Vicki L. Groo, Pharm.D., Krista M. Williams, Pharm.D., Larisa H. Cavallari, Pharm.D., Thomas D. Stamos, M.D.; University of Illinois at Chicago, Chicago, IL

Clinical Administration

41. Impact of Pharmacist Involvement at Discharge on Compliance with The Joint Commission Heart Failure Core Measure.
Holly Herring, Pharm.D., Toni Ripley, Pharm.D., Kevin Farmer, Ph.D., Winter Smith, Pharm.D.; The University of Oklahoma College of Pharmacy, Oklahoma City, OK

Dermatology

59. Safety of Biologic Treatments for Moderate to Severe Plaque Psoriasis: A Systematic Review, Basic Meta-analysis, and Bayesian Mixed Treatment Comparison.
Erica L. Baker, Pharm.D., 1 Craig I. Coleman, Pharm.D., 2 Kurt M. Reinhart, Pharm.D., 1 Olivia J. Phung, Pharm.D., 3 Ajibade Ashaye, MBBS, MPH, 1 Lisa Kugelman, M.D., 1 Wendy T. Chen, Pharm.D., 4 C. Michael White, Pharm.D., FCCP, FCP, 2 Jeff Mather, M.S., 1 Carla M. Mamolo, Ph.D., 5 Joseph C. Cappelleri, Ph.D., 6 William L. Baker Jr, Pharm.D., 7; (1) Health Outcomes, Policy and Economics (HOPE) Collaborative Group, Hartford, CT; (2) University of Connecticut, Hartford, CT; (3) Western University of Health Sciences, Pomona, CA; (4) Beth Israel Deaconess Medical Center, Boston, MA; (5) Pfizer Inc, Groton, CT; (6) Pfizer, Inc, Groton, CT; (7) University of Connecticut School of Pharmacy, Farmington, CT

Education/Training

61. Ready AND Willing: A Self-Assessment Tool to Determine Student Pharmacists’ Confidence to Optimize Drug Therapy.
Stuart T. Haines, Pharm.D., BCPS, Lisa Lebovitz, J.D., Deborah A. Sturpe, Pharm.D., BCPS, David Roffman, Pharm.D., BCPS; University of Maryland School of Pharmacy, Baltimore, MD

62E. Assessment of Students’ Readiness for Self-Directed Learning.
Therese Poirier, Pharm.D., MPH, 1 Radhika Devraj, Ph.D., 2; (1) Southern Illinois University–Edwardsville, Edwardsville, IL; (2) Southern Illinois University–Edwardsville School of Pharmacy, Edwardsville, IL
63. Improving Student Desires to Advocate for the Pharmacy Profession After Attendance to a State Board of Pharmacy Meeting.
Kristine C. Willett, Pharm.D., Cheryl R. Durand, Pharm.D., Alicia R. Desilets, Pharm.D.; Massachusetts College of Pharmacy and Health Sciences, Manchester, NH

64. Perception of Advanced Pharmacy Practice Experience Students on Inpatient Internal Medicine Rotations: A Health Care Provider Perspective.
Jason W. Lancaster, Pharm.D., BCPS, Margarita V. DiVall, Pharm.D., BCPS, Mark A. Douglass, Pharm.D., Michael J. Gonyeau, Pharm.D., BSPharm, BCPS, Adam B. Woolley, Pharm.D., Adrian Wong, B.S.; Northeastern University School of Pharmacy, Boston, MA

65. Qatar University Pharmacy Students’ Interest and Concerns Related to International Professional Experience Rotations.
Sara Al-Dahir, Pharm.D., BCPS, Sarah Amering, Pharm.D.; Xavier University of Louisiana, New Orleans, LA

66E. BA4LL: Bounce Around 4 Larger Learning. Utilization of Exercise Balls for Chairs on an Internal Medicine APPE.
Tracey L. Mersfelder, Pharm.D.; Ferris State University, Big Rapids, MI

67. Impact of aWeb-Based Learning Module and Faculty Preceptor on Experiential Pharmacy Students’ Pain Management Confidence and Competence.
Mark A. Douglass, Pharm.D.,¹ Jason Lancaster, Pharm.D., BCPS,¹ Margarita V. DiVall, Pharm.D., BCPS,² Michael J. Gonyeau, Pharm.D., BSPharm, BCPS,² Adam Woolley, Pharm.D., BCPS²; (1)Northeastern University Department of Pharmacy Practice/Boston Medical Center, Boston, MA; (2)Northeastern University School of Pharmacy, Boston, MA

68. Prospective Evaluation of Student-Led Presentations as a Successful Teaching Method for Achieving Critical Care Competency.
Daniel R. Malcom, Pharm.D., Jennifer L. Hibbs, Pharm.D., BCPS; Sullivan University College of Pharmacy, Louisville, KY

69. Dietary Supplement Education in a Senior Population.
Kimberly G. Elder, Pharm.D.,¹ Sarah A. Nisly, Pharm.D., BCPS²; (1)Indiana University Health Methodist Hospital, Indianapolis, IN; (2)Butler University College of Pharmacy and Health Sciences, Indianapolis, IN

70. Patient-Focused Pharmacotherapy Notes in a Cardiovascular Therapeutics Course: A Standardized Approach.
Angela O. Shogbon, Pharm.D., BCPS, Lisa M. Lundquist, Pharm.D., BCPS, Kathryn M. Momary, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

71. Community Pharmacists in the State of Qatar: A Survey of Their Smoking Cessation Knowledge and Educational Interests.
Maguy S. El Hajj, Pharm.D., Reem R. Al Nakeeb, BSPharm Candidate, Rajaa A. Al Qudah, BSPharm Candidate; Qatar University College of Pharmacy, Doha, Qatar

72. Pharmacy Students’ Attitudes Toward Pharmaceutical Care in Qatar.
Maguy S. El Hajj, Pharm.D., Ayat S. Hammad, BSPharm Candidate, Hebataila M. Afifi, BSPharm Candidate; Qatar University College of Pharmacy, Doha, Qatar
73. Implementation of and Experience with a Locally Developed Summative Exit Exam Delivered to Pharm.D. Students Prior to Graduation.
Lamis Karaoui, Pharm.D., BCPS, Hani Dimassi, Ph.D.; Lebanese American University, Byblos, Lebanon

74. Evaluation of Student Pharmacists’ Awareness and Perceptions of Board Certification.
Kristina D. Wood, Pharm.D.,¹ Bella H. Mehta, Pharm.D.,¹ Maria Pruchnicki, Pharm.D.,¹ Jennifer L. Rodis, Pharm.D.,¹ Kyle Porter, MAS²; (1)The Ohio State University College of Pharmacy, Columbus, OH; (2)Ohio State University Center for Biostatistics, Columbus, OH

75. Student-Created Public Service Announcements: A Novel Approach to Attaining Public Health Competency in the Pharmacy Curriculum.
Kim Coley, Pharm.D.; University of Pittsburgh School of Pharmacy, Pittsburgh, PA

76. Impact of Unlimited Access to Asynchronous Online Lecture Viewing on Student Outcomes in a Therapeutics Course.
Suzanne G. Bollmeier, Pharm.D., BCPS, AE-C, Amy Drew, Pharm.D., BCPS, Philip J. Wenger, Pharm.D., BCPS, Alicia B. Forinash, Pharm.D., BCPS; St. Louis College of Pharmacy, St. Louis, MO

78. Communication of Clinical Recommendations During Patient Case–Based Cardiovascular Therapeutics Oral Examinations.
Lisa M. Lundquist, Pharm.D., BCPS, Angela O. Shogbon, Pharm.D., BCPS, Kathryn M. Momary, Pharm.D.; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

79. The Process of Assessing Student Performance: Is Creating a Rubric the Answer?
Jayne E. Lepage, Pharm.D., Abir O. Kanaan, Pharm.D., Jennifer L. Donovan, Pharm.D.; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

80. Current State of Teaching Oncology Pharmacotherapy: Focus on Cancer as a Chronic Disease.
Michael Newton, Pharm.D., BCOP¹, Myke Green, Pharm.D., BCOP², Christopher Campen, Pharm.D., BCPS, Terry Schwinghammer, Pharm.D., BCPS¹; (1)Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, WV; (2)Department of Hematology and Medical Oncology, Arizona Cancer Center, Tucson, AZ

81E. Using Standardized Colleagues to Develop Interprofessional Communication Skills.
Susan Meyer, Ph.D.,¹ Hollis Day, M.D.,² Helen Burns, Ph.D.³; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)University of Pittsburgh School of Medicine, Pittsburgh, PA; (3)Excelsa Health, Greensburg, PA

82. Student Perceptions of Large-Scale Interprofessional Education Events.
John E. Murphy, Pharm.D.,¹ Lynne Tomasa, Ph.D.,² Andreas Theodorou, M.D.,² Cathleen Michaels, Ph.D., R.N.,³ Nancy Coleman, B.S.,² Doug Taren, Ph.D.⁴; (1)The University of Arizona College of Pharmacy, Tucson, AZ; (2)The University of Arizona College of Medicine, Tucson, AZ; (3)The University of Arizona College of Nursing, Tucson, AZ; (4) The University of Arizona College of Public Health, Tucson, AZ
83. Evaluation of Pharmacy Students’ Clinical Interventions and Estimated Cost Avoidance During a General Medicine Rotation.
Daniel R. Stevens, B.S., Adam B. Woolley, Pharm.D., BCPS, Michael T. Brennan, Pharm.D.; (1)Northeastern University, Boston, MA; (2)Northeastern University Department of Pharmacy Practice, Boston, MA; (3)VA Boston Health Care System, West Roxbury, MA

84. Knowledge and Attitude of Clinical Pharmacy Faculty Toward, and Issues Related to, Behind-the-Counter Drug Program.
Vishal Bali, M.S., Digvijay Yeola, MBA, Sujit S. Sansgiry, Ph.D.; Department of Clinical Sciences and Administration, College of Pharmacy, University of Houston, Houston, TX

85. Faculty Development Activities in U.S. Pharmacy Schools.
Holley Rice, Pharm.D., Michael G. Kendrach, Pharm.D., BSNPharm, F ASHP; McWhorter School of Pharmacy, Birmingham, AL

86. Pre-pharmacy Biomedical Literature Experience: A Survey of Pharmacy Student Self-Perception and Ability to Identify Literature Types.
Valerie A. Coppenrath, Pharm.D., Evan R. Horton, Pharm.D., Kimberly A. Pesaturo, Pharm.D.; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

87. Pharmacy Student Knowledge Retention After Completing a Simulation Utilizing High-Fidelity Mannequins Compared to a Written Patient Case.
Douglas Wylie, Pharm.D., Shaunta Ray, Pharm.D., BCPS, Andrea S. Franks, Pharm.D., BCPS, A. Shaun Rowe, Pharm.D., BCPS; (1)The University of Tennessee Medical Center, Knoxville, TN; (2)The University of Tennessee College of Pharmacy, Knoxville, TN

88. Evaluating the Impact of Implementing Pharmacy Cardiology Rounds on Student Exam Performance in a Pharmacotherapeutics Course.
Fae Wooding, Pharm.D., Michael Steinberg, Pharm.D., Kristine C. Willett, Pharm.D., Jennifer L. Donovan, Pharm.D., Abir O. Kanaan, Pharm.D.; (1)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA; (2)Massachusetts College of Pharmacy and Health Sciences, Manchester, NH

89E. Development and Evaluation of a Rubric to Assess Value of Student WIKI Contributions.
Bonnie A. Falcione, Pharm.D., BCPS, Denise L. Howrie, Pharm.D., Susan M. Meyer, Ph.D.; University of Pittsburgh School of Pharmacy, Pittsburgh, PA

Endocrinology

94. Utilization of Home Telehealth Monitoring with Active Medication Management by Clinical Pharmacists in Poorly Controlled Diabetic Patients.
Kristen J. Davis, Pharm.D., Jessica L. Wallace, Pharm.D., Jim Wan, Ph.D., M. Shawn McFarland, Pharm.D.; (1)Veterans Affairs Tennessee Valley Health Care System, Nashville, TN; (2)University of Tennessee Health Sciences Center, Memphis, TN

95E. Trends in Hyponatremia Management and Associated Outcomes in Hospital Settings: Interim Results from an Observational, Prospective, Multicenter, Global Registry in Hospitalized Patients.
Joseph Dasta, M.S., R.Ph., Alpes Amin, M.D., Jun Chiong, M.D., Arthur Greenberg, M.D., Paul Hauptman, M.D., Joseph G. Verbalis, M.D.; (1)College of Pharmacy, The
96E. Dapagliflozin Monotherapy and Combination Therapy Reduces Hyperglycemia in Patients with Type 2 Diabetes.

John R. White Jr, Pharm.D., PA-C,1 Arnaud Bastien, M.D.,2 Shamik Parikh, M.D.,3 Veronika Hruba, M.D.,4 Afshin Salsali, M.D.,2 Lisa Ying, Ph.D.,2 Jennifer Sugg, M.S.,3 James F. List, M.D., Ph.D.2; (1)Washington State University, Spokane, WA; (2)Bristol-Myers Squibb, Princeton, NJ; (3)AstraZeneca, Wilmington, DE; (4)AstraZeneca, Prague, Czech Republic

97E. Linagliptin Effectively Reduces HbA1c Independent of Age in Patients with Type 2 Diabetes.

Marc Rendell, M.D.,1 Steven Chrysant, M.D.,2 Angela Emser, M.D.,3 Max von Eynatten, M.D.,4 Sanjay Patel, MB, ChB,4 Angelina Trujillo, M.D.,5 Hans-Juergen Woerle, M.D.3; (1)Creighton Diabetes Center, Omaha, NE; (2)Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma School of Medicine, Oklahoma City, OK; (3)Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; (4)Boehringer Ingelheim Corp, Bracknell, United Kingdom; (5)Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT

98. The Effect of Basal-Bolus Insulin vs. Sliding-Scale Insulin on Quality Indicators in Hospitalized Patients with Type 2 Diabetes Mellitus on Hemodialysis.

Francine D. Salinitri, Pharm.D.,1 Neha Desai, Pharm.D.,2 Teuta Karkanfile, Pharm.D. Candidate,1 David W. Satterthwaite, Pharm.D. Candidate,1 Opada Alzohaili, M.D.,3 David A. Wilpula, Pharm.D., BCPS2; (1)Wayne State University, Detroit, MI; (2)Oakwood Hospital and Medical Center, Dearborn, MI; (3)Sinai Grace Hospital, Detroit, MI


Luigi Brunetti, Pharm.D.,1 Saira Choudry, Pharm.D.,1 Djibril S. Camara, M.D.,2 Jianming He, M.A., MEd, M.S.2; (1)Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ; (2)University of Medicine and Dentistry of New Jersey, Piscataway, NJ

Geriatrics

102F. GFR Equations Overestimate Creatinine Clearance in Elderly Individuals Enrolled in the NIA-Baltimore Longitudinal Study on Aging (BLSA).

Thomas C. Dowling, Pharm.D., Ph.D.,1 John D. Sorkin, M.D., Ph.D.,2 Luigi Ferrucci, M.D., Ph.D.3; (1)Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD; (2)Division of Gerontology, University of Maryland School of Medicine, Baltimore, MD; (3)Biomedical Research Center, National Institute on Aging, Baltimore, MD

103. Targeting Testosterone Concentrations in Elderly Males Using Transdermal Testosterone Gel.

Joseph P. Vande Griend, Pharm.D.,1 Tammie K. Nakamura, M.A.,2 Daniel W. Barry, M.D.,2 Pamela Wolfe, M.S.,3 John M. Kittelson, Ph.D.,3 Wendy M. Kohrt, Ph.D.,2 Robert S. Schwartz, M.D.3; (1)University of Colorado, School of Pharmacy, Aurora, CO; (2)...
University of Colorado, School of Medicine, Aurora, CO; (3) Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO

104. Assessing the Appropriateness of Proton Pump Inhibitor Utilization in Hospitalized Elderly Patients.
Cheryl R. Durand, Pharm.D., Kristine C. Willett, Pharm.D., Alicia R. Desilets, Pharm.D.; Massachusetts College of Pharmacy and Health Sciences, Manchester, NH

Health Services Research

Alan J. Zillich, Pharm.D., Margie E. Snyder, Pharm.D., MPH, Heather Jaynes, R.N., M.S., Jeff Harrison, Ph.D., Carl de Moor, Ph.D., Dustin D. French, Ph.D., Karen S. Hudmon, Ph.D., M.S.; (1) Purdue University College of Pharmacy, Indianapolis, IN; (2) University of Auckland School of Pharmacy, Auckland, New Zealand; (3) REGISTRAT-MAPI, Lexington, KY; (4) Roudebush VA Medical Center, Health Services Research and Development, Indianapolis, IN

Chu-Chun Chen, B.S., Tzu-Hsuan Lu, B.S., Yung-Ching Liu, M.D., Shiu-Yu Chien, M.S., Ming-Der Chao, M.S., Wuan-Jin Leu, M.S.; (1) Department of Pharmacy, Shuang Ho Hospital, Taipei Medical University, New Taipei, Taiwan; (2) Division of Infection Diseases, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei, Taiwan

Daniel M. Hartung, Pharm.D., MPH, Ann Hamer, Pharm.D., Dean Haxby, Pharm.D., Luke Middleton, B.S., Lyle J. Fagnan, M.D.; (1) Oregon State University/Oregon Health & Science University, College of Pharmacy, Portland, OR; (2) Oregon State University/Oregon Health & Science University, Portland, OR; (3) Oregon State University, Portland, OR; (4) Oregon Health & Science University, Portland, OR

Hematology/Anticoagulation

110. Implementation of a Standardized Computerized Physician Order Entry Set for Warfarin Reversal Improves Evidence-Based Administration of Vitamin K.
Jane D. Portell, Pharm.D., Craig A. McCammon, Pharm.D., Jennifer N. Riney, Pharm.D., Sebastian E. Perez, Pharm.D., Aaron Pierce, Pharm.D., Amber M. Sawyer, Pharm.D., Eli N. Deal, Pharm.D.; (1) Barnes-Jewish Hospital, St. Louis, MO; (2) BryanLGH Medical Center, Lincoln, NE; (3) University of Missouri Hospitals & Clinics, Columbia, MO

111. Obesity Affects Time to INR ≥ 1.5 in Surgical Orthopedic Patients Initiated on Warfarin for Venous Thromboembolism Prophylaxis.
Nicole E. Cieri, Pharm.D., Cynthia Lackie, Pharm.D., Kristen Kusmierski, Pharm.D.; Millard Fillmore Suburban Hospital, Williamsville, NY
112. Majority of Patients Treated with Warfarin for Atrial Fibrillation Are Willing to Switch to Dabigatran.
*Hazem F. Elewa, R.Ph., Ph.D., BCPS, Christina Deremer, Pharm.D., BCPS, Kimble Keller, Pharm.D., BCPS, Jaspal Gujral, MBBS, MRCP(UK), FACP; Georgia Health Sciences University, Augusta, GA*

*Candice L. Garwood, Pharm.D.,¹ Jennifer L. Johnson, Pharm.D.,² Shannon Habermas, Pharm.D. Student,¹ Peter Whittaker, Ph.D.³; (1)Wayne State University, Detroit, MI; (2) Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI; (3)Wayne State University School of Medicine, Cardiovascular Research Institute and Department of Emergency Medicine, Detroit, MI*

114. Timing of Venous Thromboembolism Following Total Knee or Hip Replacement.
*Beth L. Nordstrom, Ph.D., MPH,¹ Kathy Fraeman, S.M.,² Edith A. Nutescu, Pharm.D.,³ Jeff Schein, Ph.D., MPH,⁴ Braham Bookhart, MBA, MPH⁵; (1)United BioSource Corp, Lexington, MA; (2)United BioSource Corp, Lexington, MA; (3)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (4)Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ*

115. Outcomes Associated with Enoxaparin Use Among Patients with Varying Renal Function.
*Megan A. Clairmont, Pharm.D.,¹ Douglas D. DeCarolis, Pharm.D., BCPS,² Joey Thorson, Pharm.D.,² Amy Leuthner, Pharm.D.²; (1)Minneapolis Veteran Affairs Health Care System, Minneapolis, MN; (2)Minneapolis Veterans Affair Medical Center, Minneapolis, MN*

116. Bleeding Rates Among Patients with Morbid Obesity Treated with Enoxaparin.
*Jennifer C. Hagopian, Pharm.D., Jennifer N. Riney, Pharm.D., James M. Hollands, Pharm.D., Eli N. Deal, Pharm.D.; Barnes-Jewish Hospital, St. Louis, MO*

117. Retrospective Analysis of Unfractionated Heparin Infusions in Obese Patients.
*Ann N. Biesboer, Pharm.D.,¹ William J. Peppard, Pharm.D.,¹ Garret L. Newkirk, Pharm.D.,¹ David J. Hermann, Pharm.D.,¹ Bethanne M. Held, Pharm.D.,¹ James G. Gosset, M.D.²; (1) Froedert Hospital, Milwaukee, WI; (2)Medical College of Wisconsin, Milwaukee, WI*

118. Determining Optimal Vitamin K Dosing to Reverse Anticoagulation Based on Baseline INR, Route of Administration, and Home Warfarin Dose.
*Laura V. Tsu, Pharm.D., Erin Dienes, M.S., William Dager, Pharm.D.; University of California, Davis Medical Center, Sacramento, CA*

**Medication Safety**

*Grace M. Kuo, Pharm.D., Ph.D., MPH,¹ Daniel Touchette, Pharm.D., M.A.,² Jacqueline S. Marinac, Pharm.D.³; (1)UCSD, La Jolla, CA; (2)University of Illinois at Chicago, Chicago, IL; (3)ACCP Research Institute, Lenexa, KS*
Oncology

181. Characteristics and Clinical Course of Pediatric Patients Admitted with Chemotherapy-Related Febrile Neutropenia.
Suha M. Al-Omar, Pharm.D., Lama H. Nazer, Pharm.D., BCPS; King Hussein Cancer Center, Amman, Jordan

182E. ENESTnd Trial: 24-Month Follow-up of Nilotinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Gerry Gorospe III, R.N., BSN, PHN, MSN,1 Hagop M. Kantarjian, M.D.,2 Andreas Hochhaus, M.D.,3 Richard A. Larson, M.D.,4 Giuseppe Saglio, M.D.,5 Timothy P. Hughes, M.D.6; (1)City of Hope, Duarte, CA; (2)University of Texas, M.D. Anderson Cancer Center, Houston, TX; (3)Hematologie und internistische Onkologie, Universitatsklinikum Jena, Jena, Germany; (4)University of Chicago Medical Center, Chicago, IL; (5)University of Turin, Ospedale San Luigi Gonzaga, Orbassano-Turin, Italy; (6)Royal Adelaide Hospital, Adelaide, SA, Australia

183E. Deeper Responses Achieved with Switch to Nilotinib in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase with Suboptimal Molecular Response to Imatinib.
Susan Strauch, R.Ph., BCOP,1 Carole Miller, M.D.,1 Sikander Ailawadhi, M.D.,2 Anand Jillella, M.D.,3 Jerald Radich, M.D.,4 Daniel DeAngelo, M.D.,5 Stuart Goldberg, M.D.,6 Solveig Ericson, M.D.,7 Felice Lin, Pharm.D.,7 Luke Akard, M.D.8; (1)Saint Agnes Hospital, Baltimore, MD; (2)USC/Norris Comprehensive Cancer Center, Los Angeles, CA; (3)Medical College of Georgia, Augusta, GA; (4)Fred Hutchinson Cancer Research Center, Seattle, WA; (5) Dana-Farber Cancer Institute, Boston, MA; (6) John Theurer Cancer Center, Hackensack, NJ; (7) Novartis Pharmaceuticals Corp, East Hanover, NJ; (8) Indiana Blood and Marrow Transplantation, Beech Grove, IN

184E. Association Between Chronic Myeloid Leukemia Treatment Responses and Patient Satisfaction, Functioning, and Quality of Life: Patient Survey Results.
Stuart Goldberg, M.D.,1 Vamsi Bollu, Ph.D.,2 Robert Morlock, Ph.D.,3 Aleksandr Niyazov, Pharm.D.,2 Amy Guo, Ph.D.,2 Elias Jabbour, M.D.4; (1) John Theurer Cancer Center, Hackensack, NJ; (2) Novartis Pharmaceuticals Corp, East Hanover, NJ; (3) i3 Innovus, Eden Prairie, MN; (4) UT M.D. Anderson Cancer Center, Houston, TX

185E. Adherence Patterns and Dose Adjustments with Second-line Nilotinib and Dasatinib in Patients with Chronic Myeloid Leukemia: Evaluation in a Real-World Setting.
Annie Guerin, M.S.,1 Vamsi Bollu, Ph.D.,2 Amy Guo, Ph.D.,2 James D. Griffin, M.D.,3 Andrew P. Yu, Ph.D.,1 Eric Wu, Ph.D.1; (1) Analysis Group, Boston, MA; (2) Novartis Pharmaceuticals Corp, East Hanover, NJ; (3) Dana-Farber Cancer Institute, Boston, MA

Michael Mauro, M.D.,1 Jorge Cortes, M.D.,2 Richard A. Larson, M.D.,3 Peter M. Herout, Pharm.D.,4 Vamsi Bollu, Ph.D.,5 Aleksandr Niyazov, Pharm.D.,5 Amy Guo, Ph.D.,5 Hagop M. Kantarjian, M.D.6; (1) Knight Cancer Institute at Oregon Health & Science University, Portland, OR; (2) UT M.D. Anderson Cancer Center, Houston, TX; (3) University of Chicago Medical Center, Chicago, IL; (4) EPI-Q, Inc, Oak Brook, IL; (5) Novartis Pharmaceuticals Corp, East Hanover, NJ; (6) UT M.D. Anderson Cancer Center, Houston, TX
Judith A. Smith, Pharm.D., FCCP, FISOPP, BCOP; Anjali Gaikwad, M.S., Amanda Hanks, B.S., Robert Coleman, M.D.; (1) UT M.D. Anderson Cancer Center, Houston, TX; (2) UT Health Science Center at Houston Graduate School of Biomedical Sciences, Houston, TX; (4) UT M.D. Anderson Cancer Center, Houston, TX

188. Evaluation of Adverse Drug Events Associated with Liposomal Doxorubicin in Patients with Renal Insufficiency Treated for Gynecologic Malignancies.
Justin Julius, Pharm.D., Graciela Nogueras-Gonzalez, MPH, Judith K. Wolf, M.D., Judith A. Smith, Pharm.D., FCCP, FISOPP, BCOP; (1) UT M.D. Anderson Cancer Center, Houston, TX; (2) UT M.D. Anderson Cancer Center–Department of Gynecologic Oncology, Houston, TX; (3) UT M.D. Anderson Cancer Center, Houston, TX

189. Thiopurine-Associated Tumorigenesis: Using Thiopurine Methyltransferase to Identify Important Thioguanine-Induced Phenotypes in Astroglial Cells.
Amira Ahmed-Hosni, B.S., Robert Rooney, Ph.D., Joseph Barnes, M.S., Jim Wan, Ph.D., Terreia Jones, Pharm.D.; (1) University of Tennessee, Memphis; (2) Genome Explorations, Memphis, TN; (3) University of Tennessee Health Sciences Center, Memphis, TN; (4) University of Tennessee Health Sciences Center, Memphis, TN; (5) University of Tennessee, Memphis, TN

Pediatrics

205. Pharmacokinetics of Mycophenolic Acid and Glucuronidated Metabolites Following Mycophenolate Mofetil and Mycophenolate Sodium Dosing in Pediatric Renal Transplant Recipients.
Tony K.L. Kiang, Ph.D.; Mina Matsuda-Abedini, MDCM, Mary H.H. Ensom, Pharm.D.; (1) Faculty of Pharmaceutical Sciences, The University of British Columbia & Child and Family Research Institute, Vancouver, British Columbia, Canada; (2) Department of Pediatrics, Division of Nephrology, BC Children’s Hospital, Vancouver, British Columbia, Canada

206. Peroxisome Proliferator–Activated Receptor Alpha Activity Is Altered by Omega-3 Polyunsaturated Long-Chain Fatty Acids in a Cholestatic Liver Disease Model.
Emma M. Tillman, Pharm.D., Richard A. Helms, Pharm.D., Dennis D. Black, M.D.; University of Tennessee Health Science Center, Memphis, TN

209E. An NIH-Sponsored Pharmacist Curriculum on Interventions for Sudden Infant Death Syndrome (SIDS) Risk Reduction.
Hanan Kallash, M.S.; Eunice Kennedy Shriver National Institute of Child Health and Development, Baltimore, MD

211. Characterization of Cannabinoid Usage in a Pediatric Oncology Population.
Joshua J. Elder, Pharm.D.; Holly M. Knoderer, M.D.; (1) Indiana University Health, Indianapolis, IN; (2) Indiana University School of Medicine, Indianapolis, IN
212. Comparison of Single-Dose Arginine Hydrochloride to Multiple Doses of Acetazolamide to Correct Metabolic Alkalosis in Pediatric Patients.  
*Alex Oschman, Pharm.D.*, Daniel Heble Jr, Pharm.D., Tracy Sandritter, Pharm.D.; Children’s Mercy Hospital, Kansas City, MO

**Pharmacoeconomics/Outcomes**

213E. Evaluation of the HOSPITAL Resource Utilization Associated with Tolvaptan Usage Among Heart FAILURE PATIENTS with Hyponatremia FROM the Everest TRIAL.  
*Joseph Dasta, M.S., R.Ph.*, 1 Jun Chiong, M.D., MPH, 2 Sonnie Kim, Pharm.D., 3 Jay Lin, Ph.D. 4; (1)College of Pharmacy, The Ohio State University, Columbus, OH; (2)Advanced Heart Failure Program, Loma Linda University, Loma Linda, CA; (3)Otsuka America Pharmaceutical, Inc, Princeton, NJ; (4)Novosys Health, Flemington, NJ

214. The Impact of Possible Undiagnosed Heavy Menstrual Bleeding (HMB) on Presenteeism and Activities Outside of Work.  
*Mark McCoy, Pharm.D., MBA, 1 Nathalie Horowicz-Mehler, M.S., MPH, 2 Amy W. Law, Pharm.D., M.S.; (1)Bayer HealthCare Pharmaceuticals, Wayne, NJ; (2)Quintiles, Hawthorne, NY

*Jodie L. Elder, Pharm.D., BCPS, 1 Larry Custer, R.Ph., 2 Mary Wilson, NP, CDE, 3 Robert Rood, M.D., 4 Adam Wolfe, D.O.; (1)Ferris State University College of Pharmacy, Grand Rapids, MI; (2)Metro Health Hospital, Wyoming, MI; (3)St. Mary’s Health System, Grand Rapids, MI

**Pharmacoepidemiology**

*Alexandre Chan, Pharm.D., MPH, BCPS, BCOP, Yu Ko, Ph.D., Judith Kurniawan, M.D.; National University of Singapore, Department of Pharmacy, Singapore, Singapore

217. Can the Risk of Ovarian Cancer Be Reduced by the Use of Aspirin, Non-aspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen? A Large Population-Based Case-Control Study.  
*Wei-Hsuan Lo-Ciganic, M.S.*, 1 Roberta B. Ness, M.D., MPH, 2 Clareann H. Bunker, Ph.D., 1 Janice Zgibor, R.Ph., Ph.D.; (1)Department of Epidemiology, GSPH, University of Pittsburgh, Pittsburgh, PA; (2)UT School of Public Health, Houston, TX

**Pharmacogenomics/Pharmacogenetics**

*Jennifer Shaw, M.A.*, 1 Renee Robinson, Pharm.D., MPH, 1 Helene Starks, Ph.D., MPH, 2 Wylie Burke, M.D., Ph.D., 3 Denise Dillard, Ph.D.; (1)Southcentral Foundation, Anchorage, AK; (2)University of Washington, Seattle, WA
220F. Endothelial Nitric Oxide Synthase Polymorphisms and Endothelial Function in Coronary Artery Disease Patients.
Savanna Steele, Pharm.D.,¹ Bryant Tran, Pharm.D., M.S.,¹ Kyle J. Ellis, Pharm.D.,¹ Almasa Bass, Pharm.D.,¹ Robert N. Schuck, Pharm.D.,¹ Melissa Caughey, RVT, MPH,² George A. Stouffer, M.D.,² Alan L. Hinderliter, M.D.,² Craig R. Lee, Pharm.D., Ph.D.¹; (1)Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; (2)Division of Cardiology; School of Medicine, University of North Carolina, Chapel Hill, NC

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

223F. Exposure-Response Analysis of Eslicarbazepine Acetate Adjunctive Treatment of Patients with Partial-Onset Seizures.
Jahnavi Kharidia, Ph.D.,¹ Julie Passarell, M.A.,² Gary Maier, Ph.D.,¹ Jacqueline Zummo, M.S., MPH, MBA,¹ Elizabeth Ludwig, Pharm.D.,² Ted Grasela, Pharm.D., Ph.D.,² Jill Fiedler-Kelly, M.S.²; (1)Sunovion Pharmaceuticals, Inc, Marlborough, MA; (2)Cognigen Corp, Buffalo, NY

235F. Dexamethasone Systemic Exposure Is Associated with Hyperlipidemia in Children with Acute Lymphoblastic Leukemia.
Jitesh D. Kawedia, DrPh, Ph.D., Wenjian Yang, Ph.D., Deqing Pei, M.S., John C. Panetta, Ph.D., Xiangjun Cai, Ph.D., Cheng Cheng, Ph.D., Chengcheng Liu, B.S., Scott C. Howard, M.D., William E. Evans, Pharm.D., Ching-Hon Pui, M.D., Mary V. Relling, Pharm.D.; St. Jude Children’s Research Hospital, Memphis, TN

Psychiatry

244E. Risperidone-Associated Prolactin Elevation and Markers of Bone Turnover During Acute Treatment.
Jeffrey R. Bishop, Pharm.D., M.S., BCPP,¹ Leah H. Rubin, Ph.D.,² James L. Reilly, Ph.D.,² Mani N. Pavuluri, M.D., Ph.D.,² John A. Sweeney, Ph.D.²; (1)University of Illinois at Chicago College of Pharmacy, Chicago, IL; (2)University of Illinois at Chicago Center for Cognitive Medicine, Chicago, IL

245. Antipsychotic Adherence and Discontinuation Outcomes in Schizophrenia Patients with Metabolic Comorbidities: Analysis of 24 State Medicaid Programs.
Iftekhar Kalsekar, Ph.D.,¹ Raymond Mankoski, M.D., Ph.D.,² Dana Goldman, Ph.D.,³ Darius Lakdawalla, Ph.D.,³ Seth Seabury, Ph.D.,¹ Diane Ammerman, Pharm.D.,⁵ Zia Rahman, Ph.D., MBA,² Robert Forbes, Ph.D.⁶; (1)Health Services, U.S. Medical, Bristol-Myers Squibb, Plainsboro, NJ; (2)Bristol-Myers Squibb, Plainsboro, NJ; (3)Schaeffer Center for Health Policy and Economics, Los Angeles, CA; (4)RAND Corp, Santa Monica, CA; (5)Bristol-Myers Squibb, Cranberry Twp, PA; (6)Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, NJ

246E. Determining Rates of Metabolic Monitoring in Clozapine-Treated Outpatients: Evaluating the Need for a Collaborative Metabolic Monitoring Service.
Ted J. Turner, Pharm.D.,¹ Jamie L. Montgomery, R.Ph., BCPP,¹ Melissa S. McGivney, Pharm.D., FCCP,² Kim C. Coley, Pharm.D., FCCP,² Tanya J. Fabian, Pharm.D., Ph.D., BCPP¹; (1)Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA
247. Impact of a Pharmacist on Length of Stay and Readmission Rate at an Academic Inpatient Psychiatric Unit.
Kimberly Tallian, Pharm.D., FCCP, FASHP, BCPP,1 Gwendolyn Le, Pharm.D. Candidate,2 Duy Q. Tran, Pharm.D. Candidate,2 Sohil N. Rai, Pharm.D. Candidate2; (1)Scripps Memorial Hospital, La Jolla, San Diego, CA; (2)University of California, San Diego, San Diego, CA

Philip J. Wenger, Pharm.D., BCPS, Kyle R. Mays, Pharm.D.; St. Louis College of Pharmacy, St. Louis, MO

Transplant/Immunology

269F. Cardiovascular Events and CV-Related Mortality After Renal Transplantation: Effect of Maintenance Steroid Therapy and Preexisting Coronary Artery Disease.
Adele R. Shields, Pharm.D.,1 Nicole M. Schmidt, Pharm.D.,1 Rita R. Alloway, Pharm.D.,1 Michael Cardi, M.D.,2 Amit Govil, M.D.,3 Dennis Hanseman, M.S.,1 E. Steve Woodle, M.D.; (1)University of Cincinnati, Cincinnati, OH; (2)The Christ Hospital, Cincinnati, OH; (3)The Health Alliance, Cincinnati, OH

Women’s Health

Kylie N. Barnes, Pharm.D.,1 Alicia B. Forinash, Pharm.D., BCPS,2 Laurie Niewoehner, Pharm.D.,3 Jeffrey Greenspoon, M.D.; (1)St. Louis College of Pharmacy, St. Louis, MO; (2)St. Louis College of Pharmacy, St. Louis, MO; (3)St. Mary’s Health Center, St. Louis, MO; (4)St. Louis University, St. Louis, MO

CLINICAL PHARMACY FORUM

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

Cardiovascular

Paula Horn, Pharm.D., BCPS, CACP, Laura Krumenacker, Pharm.D., Edward T. Horn, Pharm.D., BCPS, Robert J. Moraca, M.D., Walter E. McGregor, M.D., Srinivas Murali, M.D., George G. Sokos, D.O., Raymond L. Benza, M.D., Stephen H. Bailey, M.D.; Allegheny General Hospital, Pittsburgh, PA

Lisa M. Perry, Pharm.D., Mei Tse, Pharm.D.; Portland Veterans Affairs Medical Center, Portland, OR
295. The Implications of Clopidogrel Black Box Warning on Utilization of Platelet Aggregation Testing in the Community Hospital Setting.
Kathryn M. Momary, Pharm.D.,¹ Kevin Sponsel, Pharm.D. Candidate,¹ Kelly Blanchfield, Pharm.D.²; (1)Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (2)Saint Joseph’s Hospital of Atlanta, Sandy Springs, GA

Clinical Administration

Kena Lanham, Pharm.D., LaDonna S. Cangany, CPhT; Saint Vincent Hospital, Indianapolis, IN

297. Implementation of Telepharmacy Services in a Multihospital Health System.
Matthew Jenkins, Pharm.D., M.S., Madalyn Bates, R.Ph., Meredith Jernigan, Pharm.D., Deborah Redmond, MBA, MHA; University of Pittsburgh Medical Center, Pittsburgh, PA

298. Warfarin Monitoring by Pharmacists versus Usual Standard of Care in a Long-term Acute Care Hospital.
Helen Feinstein, Pharm.D., BCPS; Kindred Hospital, Pittsburgh, PA

Education/Training

310E. Assessing the Effect of Multiple Advanced Cardiac Life Support Simulations on Pharmacy Student Performance.
Jason S. Haney, Pharm.D., BCPS,¹ Sarah P. Shrader, Pharm.D., BCPS²; (1)South Carolina College of Pharmacy, Charleston, SC; (2)South Carolina College of Pharmacy/MUSC Medical Center, Charleston, SC

311. Evaluation of a 20-Week Longitudinal Student Program.
Kelly M. Wright, Pharm.D., Amy L. Dzierba, Pharm.D.; New York-Presbyterian Hospital, New York, NY

Monica L. Miller, Pharm.D., M.S., Rakhi Karwa, Pharm.D., Ellen M. Schellhase, Pharm.D., Sonak D. Pastakia, Pharm.D., MPH, Imran Manji, BSPharm; Purdue University, Indianapolis, IN

313. Expanding Residency Opportunities Through School of Pharmacy Collaborations.
Heather J. Johnson, Pharm.D.,¹ Amy L. Seybert, Pharm.D.²; (1)UPMC Department of Pharmacy and Therapeutics, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

314. Utilization of Cloud Computing to Aid Experiential Precepting at a Tertiary Academic Medical Center.
Maria Giannakos, Pharm.D., MBA, Timothy Pasquale, Pharm.D.; Summa Health System – Akron City Hospital, Akron, OH

315. Pharmacist-Physician Interdisciplinary Faculty Development: Get Out of Your Silo!
Trish Klatt, Pharm.D., BCPS,¹ Heather A. Sakely, Pharm.D., BCPS,¹ Stephen A. Wilson, M.D., MPH, FAAFP²; (1)UPMC St. Margaret, Pittsburgh, PA; (2)University of Pittsburgh Family Medicine Faculty Development Fellowship, UPMC St. Margaret Family Medicine Residency, Pittsburgh, PA
Kathryn M. Momary, Pharm.D., Lisa M. Lundquist, Pharm.D., BCPS; Mercer University College of Pharmacy and Health Sciences, Atlanta, GA

Geriatrics

324E. Characteristics Associated with Clinical Pharmacist Interventions Among Home-Based Primary Care Veterans.

Health Services Research

326. Initial Stages in the Development of an Antimicrobial Stewardship Program in a Teaching Hospital.
Ashley R. Hughes, Pharm.D.,1 Michael C. Ott, Pharm.D., BCPS,2 Randy A. Gerwitz, R.Ph.,2 Joseph A. Paladino, Pharm.D.,3 Gina M. Prescott, Pharm.D., BCPS; (1)University at Buffalo, Amherst, NY; (2)Erie County Medical Center, Buffalo, NY; (3)CPL Associates LLC, Buffalo, NY

Hematology/Anticoagulation

327. A Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome.
Sherrie Lathon, Pharm.D., Leigh Boehmer, Pharm.D., Sara Butler, Pharm.D., Kristan Augustin, Pharm.D., Ali McBride, Pharm.D., M.S.; Barnes-Jewish Hospital, St. Louis, MO

Mandana Ghodrat, Pharm.D.,1 Laleh Azari, Pharm.D.,2 Gregory Smallwood, Pharm.D.; (1)Philadelphia College of Osteopathic Medicine – School of Pharmacy, Suwanee, GA; (2)Methodist University Hospital Department of Pharmacy, Memphis, TN

329E. Evolution of an Inpatient Anti-thrombosis Service Including Adaptation to the EPIC System and Workload Assessment.
William Dager, Pharm.D., Aaron Roberts, Pharm.D., Patricia Parker, Pharm.D., Richard White, M.D.; University of California, Davis Medical Center, Sacramento, CA

Infectious Diseases

Stephanie A. Flowers, Pharm.D.,1 Sarah G. Whaley, B.S.,2 Katherine S. Barker, Ph.D.,1 P. David Rogers, Pharm.D., Ph.D.; (1)University of Tennessee, Memphis, TN; (2)University of Tennessee College of Pharmacy, Memphis, TN; (3)University of Tennessee Health Science Center, Memphis, TN
Oncology

339. Effects of Standardization of Urine Alkalinization for Hematology and Oncology Patients.
Patricia A. Jeppson, Pharm.D., Martha J. Glenn, M.D., Kenneth Boucher, Ph.D., J. Andrew Stuart, Pharm.D.; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Bo Yu, M.S., Bin Zhu, B.S., Qing Zhai, M.S.; Fudan University Shanghai Cancer Center, Shanghai, China

Pharmacoeconomics/Outcomes

345. Examining Knowledge and Information-Seeking Behaviors Toward Blood Transfusion Among Individuals with Chronic Kidney Disease.
Ahmad Naim, M.D., D. Walls, Ph.D., Jan Gollins, MBA, Chuck Reynolds, M.S.; (1) Centocor Ortho Biotech Services, LLC, Horsham, PA; (2)BDJ Solutions, LLC, Medford, MA; (3)Delta Modelling Group, Mount Prospect, IL; (4)The Benfield Group, St. Louis, MO

346. Examining the Patient-Centered Decision-making Attributes Toward Blood Transfusion Among Individuals with Chronic Kidney Disease (CKD).
Ahmad Naim, M.D., D. Walls, Ph.D., Jan Gollins, MBA, Chuck Reynolds, M.S.; (1) Centocor Ortho Biotech Services, LLC, Horsham, PA; (2)BDJ Solutions, LLC, Medford, MA; (3)Delta Modelling Group, Mount Prospect, IL; (4)The Benfield Group, St. Louis, MO

347. Quality of Life Burden in Chemotherapy-Naïve and Chemotherapy-Experienced Men with Metastatic Prostate Cancer.
Mekre Senbetta, Pharm.D., Jamie Forlenza, Pharm.D., Amy Smalarz, Ph.D., Kimberly Riggs, B.S.; (1) Centocor Ortho Biotech Services, LLC, Horsham, PA; (2) United BioSource Corp, Lexington, MA

Ana Leandro, Pharm.D., Armando Alcobia, Pharm.D.; Hospital Garcia de Orta, Almada, Portugal

Pharmacogenomics/Pharmacogenetics

350. The Quest Toward Personalized Medicine: Overview of Pharmacogenetics and Safety of Drug Therapy.
Salah M. Blaih, Ph.D., R.Ph.; Department of Chemistry and Biochemistry, Kent State University, Warren, OH

Psychiatry

351. Drug-Related Problems with Antidepressants in a Hospital Setting in India.
Anantha Naik Nagappa, Ph.D., MSPharm, Uday Venkat Mateti, BSPharm (Pharm.D.), Tarachand Lalwani, BSPharm (Pharm.D., PB), P.V. Bhandary, MBBS, M.D., Rajesh Balkrishnan, BSPharm, Ph.D., M.S.; (1) Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, India; (2) Manipal College of Pharmaceutical Sciences, Manipal, India; (3) Dr. A.V. Baliga Memorial Hospital, Udupi, India; (4) Center for Global Health and College of Pharmacy, University of Michigan
RESIDENTS AND FELLOWS RESEARCH IN PROGRESS

These papers describe original research by residents and fellows in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoepidemiology, and pharmacogenomics in which the research effort is ongoing.

ADR/Drug Interactions

Michael J. Armahizer, Pharm.D.,¹ Sandra Kane-Gill, Pharm.D., M.S., FCCM,² Pamela L. Smithburger, Pharm.D., BCPS,² Amy L. Seybert, Pharm.D.²; (1)UPMC Presbyterian, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

Adult Medicine

353. Persistent Use of Against Label Statin-Fibrate Combinations from 2003 to 2009 Despite FDA Dose Restrictions.
Julie C. Alford, Pharm.D., Joseph J. Saseen, Pharm.D., Richard R. Allen, M.S., Kavita V. Nair, Ph.D.; University of Colorado, School of Pharmacy, Aurora, CO

Ambulatory Care

354. The Role of Clinical Pharmacist in an HIV Care Team: A Retrospective Review.
Cathy Hau, Pharm.D., Kirsten Balano, Pharm.D., AAHIVE; University of California–San Francisco, San Francisco, CA

Cardiovascular

Rathasen Prom, Pharm.D.,¹ Craig Umscheid, M.D.,² Sarah A. Spinler, Pharm.D., FCCP, BCPS¹; (1)University of the Sciences in Philadelphia, Philadelphia, PA; (2)University of Pennsylvania, Philadelphia, PA

Julia M. Underwood, Pharm.D.,¹ Kelly C. Rogers, Pharm.D.,² Maria Pham, Pharm.D.,¹ Robert Parker, Pharm.D.,² Shannon W. Finks, Pharm.D.²; (1)Veterans Affairs Medical Center Memphis, Memphis, TN; (2)University of Tennessee College of Pharmacy, Memphis, TN

Critical Care

357. Incidence of Hyperglycemia in At-Risk Medical Intensive Care Unit Patients upon Cessation of Intravenous Insulin Infusions.
Erin N. Frazee, Pharm.D.,¹ Joanna L. Stollings, Pharm.D.,² Heather A. Personett, Pharm.D.,¹ Garrett E. Schramm, Pharm.D.,³ Philip J. Kuper, Pharm.D.⁴; (1)Mayo Clinic, Rochester, MN; (2)Mayo Clinic Rochester, Rochester, MN; (3)Mayo Clinic Rochester, Rochester, MN; (4)Mayo Clinic Rochester – Mayo Foundation, Rochester, MN
358. Blood Pressure Control in the Hospitalized Elderly Trauma Population.  
*Lina Saliba, Pharm.D.*, Anthony T. Gerlach, Pharm.D., FCCM, BCPS; The Ohio State University Medical Center, Columbus, OH

*A. Rebecca Bickley, Pharm.D.*, Sarah A. Young, Pharm.D., Edward C. Seidl, Pharm.D., Daniel A. Shade, M.D.; Allegheny General Hospital, Pittsburgh, PA

Education/Training

360. Teaching Emphasis Within Pharmacy Residency Programs.  
*Ibrahim Sales, Pharm.D.*,¹ Susan Meyer, Ph.D.,² Sandra Kane-Gill, Pharm.D., M.S., FCCM,² Denise Howrie Schiff, Pharm.D.²; (1)University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy, Pittsburgh, PA

*Sheryl B. Fleisch, M.D.*, Ted J. Turner, Pharm.D., Jamie Montgomery, R.Ph., BCPP, Michelle L. Gross, Pharm.D., Tanya Fabian, Pharm.D., Ph.D., BCPP; Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA

362. Prevalence of Board Certification Among Pharmacy Practice Faculty at U.S. Schools/Colleges of Pharmacy.  
*Kimberly A. Toussaint, Pharm.D.*,¹ Kristin Watson, Pharm.D., BCPS,² Joel C. Marrs, Pharm.D., BCPS,³ Deborah A. Sturpe, Pharm.D., BCPS,² Sarah L. Anderson, Pharm.D., BCPS,³ Stuart T. Haines, Pharm.D., BCPS²; (1)University of Maryland Medical Center, Baltimore, MD; (2)University of Maryland School of Pharmacy, Baltimore, MD; (3) University of Colorado School of Pharmacy, Aurora, CO

*Samantha R. Llanos, Pharm.D.*, Kelsey White, Pharm.D., Eleanor Yu, Pharm.D., Fae Wooding, Pharm.D.; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

Family Medicine

364. Use of an Adherence Estimator and Individualized Counseling for New Chronic Medication Prescriptions.  
*Robert S. Helmer, Pharm.D.*,¹ Sarah A. Treadway, Pharm.D.,¹ Michelle Z. Farland, Pharm.D., BCPS,² Shaunta’ M. Ray, Pharm.D., BCPS²; (1)University of Tennessee College of Pharmacy/University of Tennessee Medical Center, Knoxville, TN; (2)University of Tennessee College of Pharmacy, Knoxville, TN

365. Evaluation of an Electronic Health Record Warfarin Documentation System Within a Family Medicine Residency Program.  
*Nicole D’Antonio, Pharm.D.*, Roberta Farrah, Pharm.D., BCPS; UPMC St. Margaret Hospital, Pittsburgh, PA
Geriatrics

366. The Use of Valproic Acid or Oxcarbazepine to Treat Dementia-Related Agitation.  
Rachel L. Freytag, Pharm.D., Jessica K. Cather, Pharm.D., BCPS, Susan M. Fosnight, R.Ph., CGP, BCPS, Dorcas J. Letting, Pharm.D., BCPS; Summa Health System, Akron, OH

367. The Effect of Haloperidol Loading Dose on the Duration of Delirium.  

Hematology/Anticoagulation

368. Comparison of aPTT vs. Anti-Xa Assay for the Therapeutic Monitoring of Unfractionated Heparin.  
Darko Todorov, Pharm.D., Michael Cunningham, Pharm.D., Suzanne Conyne-Rapin, Pharm.D.; UC Health-University Hospital, Cincinnati, OH

369. Evaluation of Compliance to American College of Chest Physicians Guidelines for Warfarin Reversal with Vitamin K.  
Giavanna M. Russo-Alvarez, Pharm.D., Stacey Miske, Pharm.D., Leslie Gingo, Pharm.D.; (1)University of Pittsburgh Medical Center St. Margaret, Pittsburgh, PA; (2)University of Pittsburgh Medical Center Northwest, Seneca, PA

Infectious Diseases

Khusbu Patel, Pharm.D., William Kernan, Pharm.D., BCPS; Cleveland Clinic Florida, Weston, FL

371. Review of Anidulafungin Utilization in Patients with Hepatic Dysfunction at a Large Academic Medical Center.  

372. Does In Vitro Resistance of Streptococcus pyogenes to Erythromycin Produce Clindamycin Resistance?  
Christine M. Bridgen, Pharm.D., Harminder Sikand, Pharm.D., Daniel Keays, M.S., CLS; Scripps Mercy Hospital, San Diego, CA

373. A Matched-Controlled Evaluation of an Antifungal Bundle in the Intensive Care Unit at a University Teaching Hospital.  
Anthony J. Guarascio, Pharm.D., Douglas Slain, Pharm.D., BCPS, Arif Sarwari, M.D., Richard L. McKnight, Pharm.D., Karen O. Petros, Pharm.D., John Parker, M.D., FACP, FCCP, Alison M. Wilson, M.D., Maria Pompili, Pharm.D., Melissa L. Rinehart, Pharm.D., Carrie Defazio, Pharm.D.; (1)West Virginia University, Morgantown, WV; (2) West Virginia University Hospitals, Morgantown, WV
374. Doripenem and Colistin Are Synergistic and Demonstrate Bactericidal Killing Against Pandrug-Resistant Klebsiella pneumoniae Isolates In Vitro.  
Meredith Jernigan, Pharm.D., Minh-Hong Nguyen, M.D., Neil Clancy, M.D., Ellen Press, B.S., Ryan Shields, Pharm.D.; University of Pittsburgh Medical Center, Pittsburgh, PA

Managed Care

375. Evaluation of a Fluticasone/Salmeterol Step-down Program.  
Lily Phuong, Pharm.D., Emily Pearse, Pharm.D., Judy Pereira, Pharm.D., Fern Chau-Devera, Pharm.D.; Kaiser Permanente Medical Care Program, Vallejo, CA

Medication Safety

376. Avoidance of Sulfonylureas in Hospitalized Patients at High Risk for Hypoglycemia: Effectiveness of an E-mail Alert.  
Ibrahim Sales, Pharm.D., Donihi Amy, Pharm.D., BCPS; University of Pittsburgh Medical Center, Pittsburgh, PA

377. Creation of a Risk Score for Predicting Opioid Harm in the Inpatient Setting.  
Jordan R. Wong, Pharm.D., Nadia Z. Haque, Pharm.D., Megan Winegardner, Pharm.D., James S. Kalus, Pharm.D.; Henry Ford Hospital, Detroit, MI

Nephrology

Magdalene M. Assimon, Pharm.D.,1 Page V. Salenger, M.D.,2 Shari Meola, R.N.,2 Darius L. Mason, Pharm.D., BCPS1; (1)Albany College of Pharmacy & Health Sciences, Albany, NY; (2)Rubin Dialysis Center, Clifton Park, NY

Neurology

379. Examining Utilization Patterns of Patients Receiving Oral Therapy for Multiple Sclerosis (MS) Treatment.  
Laura Studnicki, Pharm.D., MBA Candidate,1 Pamela H. Koerner, Pharm.D.,2 Richard T. Miller, R.Ph., MBA3; (1)Walgreens and Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA; (2)Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA; (3) Walgreens, Carnegie, PA

Oncology

Rachelle Whiteside, Pharm.D., Rickey Miller, Pharm.D., BCPS, BCOP, Kenneth Kochman, Pharm.D.; Allegheny General Hospital, Pittsburgh, PA
Pharmacogenomics/Pharmacogenetics

381. The Effect of Epithelial Sodium Channel Genotype on Loop Diuretic Requirements in Systolic Heart Failure; Interim Analysis of the First 50 Subjects.

Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

382. Prospective Trial of a Novel Vancomycin Nomogram.
Amber R. Wesner, Pharm.D.,¹ Robert S. Kidd, Pharm.D., Ph.D.,² Marcia L. Brackbill, Pharm.D., BCPS,² Larissa Coyle, Pharm.D., BCPS³; (1)Shenandoah University, Bernard J. Dunn School of Pharmacy/Valley Health, Winchester Medical Center, Winchester, VA; (2) Shenandoah University, Bernard J. Dunn School of Pharmacy, Winchester, VA; (3)Valley Health, Winchester Medical Center, Winchester, VA

Transplant/Immunology

383. Tacrolimus Trough Concentrations in Heart Transplant Recipients During Episodes of Acute Cellular Rejection.
Gretchen Kipp, Pharm.D.,¹ Michael A. Shullo, Pharm.D.,¹ Heather J. Johnson, Pharm.D., BCPS,¹ Shelby L. Corman, Pharm.D., BCPS,¹ Jeffrey Teuteberg, M.D.,² Ty Ridenour, Ph.D.,³ Raman Venkataramanan, Ph.D.; (1)UPMC Department of Pharmacy & Therapeutics, Pittsburgh, PA; (2)UPMC Cardiovascular Institute, Pittsburgh, PA; (3)University of Pittsburgh, Pittsburgh, PA

Nicole M. Schmidt, Pharm.D., E. Steve Woodle, M.D., Rita R. Alloway, Pharm.D., Gautham Mogilishetty, M.D., Amit Tevar, M.D., Stefanie Young, n/a, Liz Cole, n/a, Dennis Hanseman, M.S., Adele R. Shields, Pharm.D.; University of Cincinnati, Cincinnati, OH

Nicole M. Schmidt, Pharm.D.,¹ Adele R. Shields, Pharm.D.,¹ Rita R. Alloway, Pharm.D.,¹ Gautham Mogilishetty, M.D.,¹ Michael Cardi, M.D.,² Rino Munda, M.D.,² Amit Tevar, M.D.,¹ Justin Burns, M.D.,¹ Joseph Kremer, M.D.,² Liz Cole, n/a,¹ Stefanie Young, n/a,¹ Dennis Hanseman, M.S.,¹ Shahzad Safdar, M.D.,² E. Steve Woodle, M.D.; (1)University of Cincinnati, Cincinnati, OH; (2)The Christ Hospital, Cincinnati, OH

Basma Sadaka, Pharm.D., Rita R. Alloway, Pharm.D., Alin Girnita, M.D., Paul Brailey, Ph.D., Gautham Mogilishetty, M.D., E. Steve Woodle, M.D.; University of Cincinnati, Cincinnati, OH

387. Preservation of Renal Function with Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy Early After Heart Transplantation.
David Johnson, Pharm.D., Michael A Shullo, Pharm.D., Shelby L. Corman, Pharm.D., M.S., BCPS, Jeffrey J. Teuteberg, M.D.; University of Pittsburgh, Pittsburgh, PA